Home / Markets / News / Cipla Q1 revenue may be muted on high base, low Covid drug sales: Analysts

Cipla Q1 revenue may be muted on high base, low Covid drug sales: Analysts

Cipla Q1 results preview: Analysts attribute the likely dull performance due to the high base of last year, and the reduction in revenue contribution from Covid-19 therapies in the recent quarter.

Web Exclusive Premium

An employee works at the reception area of Cipla at its headquarters in Mumbai. Photo: Reuters

3 min read Last Updated : Jul 28 2022 | 3:15 PM IST

Mumbai-based pharma giant Cipla Ltd is set to release its June quarter earnings on Friday, July 29. Analysts expect the company to post a muted rise in revenues on a yearly basis to Rs 5,670.5 crore due to weakness in domestic sales.

Four out of five brokerages project the company’s revenue to increase by 3-6 per cent year-on-year (YoY), while the fifth, ICICI Securities, estimates a 1.2 per cent decline for the same. The adjusted profit after tax is also likely to decline by up to 25 per cent YoY to Rs 608 crore.

Analysts attribute the likely dull performance

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in